Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SATURN-style Phase III trial of early versus delayed Tarceva maintenance in EGFR wild-type advanced NSCLC
NL-OMON35789Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Early Tarceva maintenance with Placebo maintenance with delayed Tarceva at progression (2 arms). Primary endpoint: Overall survival. Started Apr 2012; status: active, not recruiting.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON35789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35789.